Estrogen receptor expression in an endometrial stromal sarcoma after tamoxif en therapy

Introduction: Several cases of low-grade endometrial stromal sarcomas in women with breast cancer have been reported to be associated with tamoxifen therapy. Estrogen receptor expression has been used to characterize the partial estrogenic action of tamoxifen on the endometrium and has been found in tamoxifen-associated endometrial pathologies.

Case: A low-grade endometrial stromal sarcoma in a woman with a history of breast cancer treated with adjuvant tamoxifen is presented. Steroid receptor studies performed on the tumor were negative for estrogen and positive for progesterone.

Conclusion: The absence of estrogen receptor expression suggests that endometrial stromal sarcomas are not necessarily caused by the estrogenic properties of tamoxifen.

Endometrial stromal sarcoma; Tamoxifen; Estrogen receptor

[1] Cohen I.,B eyth Y.,A ltaras M. M.,S hapira J., Tepper R., Cardoba M. et al.: "Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies" Gynecol. Oneal., 1997, 67, 8.

[2] Hachisuga T., Hideshima T., Kawarabayashi T., Eguchi F., Emoto M., Shirakusa T.: "Expression of steroid receptors, Ki-67, and epidermal growth factor receptor in tamoxifen-treated endometrium". Int. J. Gynecol. Pathol., 1999, 18, 297.

[3] Kommoss F., Karck U., Prompeler H., Pfisterer J., Kirkpatrick C J.:''Steroid receptor expression in endometria from women treated with tamoxifen". Gynecol. Oncol., 1998, 70, 188.

[4] Schwartz L. B., Krey L., Demopoulos R., Goldstein S. R., Nachtigall L. E., Mittal K.: "Alterations in steroid hormone receptors in the tamoxifen-treated endometrium". Am. J. Obstet. Gynecol., 1997, 176, I Part I, 129

[5] Seoud M. A., Johnson J., Weed J. C.: "Gynecologic tumors m tamoxifen treated women with breast cancer". Obstet. Gynecol., 1993, 82, 165.

[6] Beer T. W., Buchanan R.. Buckley C. H.: "Uterine stromal sarcoma following tamoxifen treatment". J. Clin. Pathol., 1995, 48, 596.

[7] Eddy G. L., Mazur M. T.: "Endolymphatic stromal myosis associated with tamoxifen use". Gynecol. Oncol., 1997, 64, 262.

[8] Fisher B., Constantino J. P., Redmond C. K., Fisher E. R., Wicherham L., Cronin W, M.: "Endometrial cancer in tamoxifen treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NBSABP)B-14", J. Natl Cancer Inst., 1994, 86, 527.

[9] Kennedy M. M., Baigrie C. F, Manek S.: "Tamoxifen and the endometrium: review of 102 cases and comparison with HRTrelated and non-HRT-related endometrial pathology". Int. J. Gynecol. Pathol., 1999, 18, 130.

[10] Pang L. C.: "Endometrial stromal sarcoma with sex-cord-like differentiation associated with tamoxifen therapy". S. Med. J., 1998, 91, 592.

[11] Bergman L., Beelen M.L.R., Gallee M.P.W., Hollema H., Benraadt J., van Leeuwen F.E., the Comprehensive Cancer Centeres ALERT Group.: "Risk and prognosis of endometrial cancer after tamoxifen for breast cancer". Lancet, 2000, 356, 881.

[12] Tosi P., Sforza V, Santopietro R.: "Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma". Obstet. Gynecol., 1989, 73, 75.